# Rybelsus, Mounjaro, Wegovy: India's weight-loss drug boom and the risks behind it - BBC

## Metadata
| Field | Value |
|-------|-------|
| Source | BBC |
| URL | https://news.google.com/rss/articles/CBMiWkFVX3lxTE0waThRR1JjZmV3RFFlX19CWjkxTXU3LWNOLTd5SFRpQnc5RDVRR3ByZTZxWDJMTmNBcGZQR3JWWmJUNzltLTczdVpMdGhwbmVIRUJTNGVqdk9DUdIBX0FVX3lxTFBUYlBMWXBtaEVpX1JzZUg0WnJMc0F1c2l3aWQxSHFia051TS1vNGllb1I1aW5aU1ZvVV9IY1Z2dTI1ZGlQSzFkVkNMbnlnelhUei1oQ3RkbnlWRm9SNzlR?oc=5&hl=en-US&gl=US&ceid=US:en |
| Scraped | 2026-01-01 07:00 |
| Category | GLP-1 |
| Relevance | 8/10 |
| Signal | bull |

## Investment Summary
Article examines market dynamics for GLP-1 weight loss medications in India, highlighting global expansion and potential regulatory/market opportunities for pharmaceutical companies developing obesity treatments.

## Key Entities
Novo Nordisk, Eli Lilly, BBC

## Dollar Amounts
None mentioned

---

## Article Content

*Full content could not be extracted. Visit URL for details.*

---

#healthcare-news #glp-1 #auto-scraped
